HC Wainwright Raises Earnings Estimates for vTv Therapeutics

vTv Therapeutics Inc. (NASDAQ:VTVT) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of vTv Therapeutics in a research report issued on Wednesday, March 11th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will earn ($0.64) per share for the quarter, up from their previous estimate of ($0.70). HC Wainwright has a “Buy” rating and a $47.00 price target on the stock. HC Wainwright also issued estimates for vTv Therapeutics’ Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.03) EPS, FY2027 earnings at ($3.33) EPS, FY2028 earnings at ($3.20) EPS, FY2029 earnings at ($3.21) EPS and FY2030 earnings at ($3.25) EPS.

Other research analysts have also recently issued research reports about the stock. BTIG Research restated a “buy” rating and issued a $49.00 price objective on shares of vTv Therapeutics in a report on Wednesday. Roth Mkm initiated coverage on shares of vTv Therapeutics in a research note on Thursday, January 22nd. They issued a “buy” rating and a $58.00 price target for the company. Wall Street Zen raised vTv Therapeutics to a “sell” rating in a research report on Saturday, December 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday, December 29th. Finally, Evercore assumed coverage on vTv Therapeutics in a research note on Thursday. They issued an “outperform” rating and a $44.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, vTv Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $53.00.

vTv Therapeutics Stock Performance

Shares of VTVT opened at $33.28 on Friday. The company’s 50-day simple moving average is $35.93 and its 200-day simple moving average is $29.42. vTv Therapeutics has a 1 year low of $14.00 and a 1 year high of $44.00. The stock has a market capitalization of $131.12 million, a PE ratio of -9.93 and a beta of 0.44.

vTv Therapeutics (NASDAQ:VTVT) last released its earnings results on Tuesday, March 10th. The biotechnology company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($1.09) by $0.51. The firm had revenue of ($0.02) million during the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP increased its holdings in vTv Therapeutics by 52.4% in the third quarter. Baker BROS. Advisors LP now owns 148,314 shares of the biotechnology company’s stock valued at $3,463,000 after buying an additional 51,000 shares during the last quarter. 683 Capital Management LLC purchased a new stake in vTv Therapeutics during the 4th quarter worth about $731,000. Geode Capital Management LLC boosted its position in shares of vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after acquiring an additional 12,896 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in shares of vTv Therapeutics during the 4th quarter worth about $221,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

Key Headlines Impacting vTv Therapeutics

Here are the key news stories impacting vTv Therapeutics this week:

• Positive Sentiment: Evercore ISI initiated coverage with an “Outperform” recommendation, providing a new institutional buy-side endorsement that can attract demand and support the share price. Evercore initiation article
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and $47 price target while raising several near-term EPS estimates (Q1–Q4 2026 and FY2026) and trimming losses for FY2027 relative to prior forecasts — a signal that the firm sees improving fundamentals in the nearer term and provides supportive analyst cover (no link available).
• Neutral Sentiment: vTv filed Q4 and full-year 2025 financial results and issued a corporate update; company results and commentary can influence sentiment depending on guidance and program milestones, so investors should review the release for pipeline/cash details. Q4/FY2025 results and corporate update
• Neutral Sentiment: Market calendars show vTv is projected to announce upcoming earnings — scheduled event risk can increase intraday volatility around the stock. Earnings projection article
• Negative Sentiment: Within the same HC Wainwright coverage notes, the firm lowered long‑range EPS assumptions (FY2028–FY2030 and FY2029 reductions), increasing projected longer-term losses. Those cuts could pressure expectations for longer-term profitability and cap upside despite near-term improvements (no link available).

About vTv Therapeutics

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.